argenx (ARGX) Expected to Announce Quarterly Earnings on Thursday

argenx (NASDAQ:ARGX) will likely be issuing its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of $0.98 per share and revenue of $678.52 million for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

argenx Stock Performance

NASDAQ ARGX opened at $624.94 on Wednesday. The business has a 50 day simple moving average of $642.66 and a 200 day simple moving average of $589.24. argenx has a 52-week low of $349.86 and a 52-week high of $678.21. The stock has a market cap of $37.97 billion, a price-to-earnings ratio of -710.16 and a beta of 0.58.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Evercore ISI raised their price target on shares of argenx from $675.00 to $706.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. HC Wainwright reiterated a “buy” rating and issued a $717.00 price objective (up from $670.00) on shares of argenx in a report on Tuesday, January 14th. Oppenheimer reiterated an “outperform” rating and issued a $675.00 price objective (up from $646.00) on shares of argenx in a report on Thursday, November 21st. William Blair upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a report on Friday, November 1st. Finally, Piper Sandler lifted their price objective on shares of argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a report on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $658.39.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.